These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

790 related items for PubMed ID: 25400755

  • 1. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
    Park S, Wang HY, Kim S, Ahn S, Lee D, Cho Y, Park KH, Jung D, Kim SI, Lee H.
    Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
    [Abstract] [Full Text] [Related]

  • 2. Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer.
    El Hadi H, Abdellaoui-Maane I, Kottwitz D, El Amrani M, Bouchoutrouch N, Qmichou Z, Karkouri M, ElAttar H, Errihani H, Fernandez PL, Bakri Y, Sefrioui H, Moumen A.
    Gene; 2017 Mar 20; 605():114-122. PubMed ID: 28039034
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
    Wang HY, Park S, Kim S, Ahn S, Lee D, Kim S, Jung D, Park KH, Lee H.
    Int J Clin Exp Pathol; 2014 Mar 20; 7(9):5792-800. PubMed ID: 25337220
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples.
    Wang HY, Kim S, Park S, Kim S, Jung D, Park KH, Lee H.
    Exp Mol Pathol; 2014 Dec 20; 97(3):368-74. PubMed ID: 25236569
    [Abstract] [Full Text] [Related]

  • 5. Quantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samples.
    Pu T, Guo P, Qiu Y, Chen S, Yang L, Sun L, Ye F, Bu H.
    Int J Clin Exp Pathol; 2015 Dec 20; 8(9):10565-74. PubMed ID: 26617766
    [Abstract] [Full Text] [Related]

  • 6. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
    Zhu Y, Lu D, Lira ME, Xu Q, Du Y, Xiong J, Mao M, Chung HC, Zheng G.
    Exp Mol Pathol; 2016 Apr 20; 100(2):287-93. PubMed ID: 26626802
    [Abstract] [Full Text] [Related]

  • 7. Clinical Usefulness of a One-Tube Nested Reverse Transcription Quantitative Polymerase Chain Reaction Assay for Evaluating Human Epidermal Growth Factor Receptor 2 mRNA Overexpression in Formalin-Fixed and Paraffin-Embedded Breast Cancer Tissue Samples.
    Wang HY, Ahn S, Park S, Kim S, Lee H.
    Pathobiology; 2017 Apr 20; 84(2):57-70. PubMed ID: 27544315
    [Abstract] [Full Text] [Related]

  • 8. Droplet Digital™ PCR quantitation of HER2 expression in FFPE breast cancer samples.
    Heredia NJ, Belgrader P, Wang S, Koehler R, Regan J, Cosman AM, Saxonov S, Hindson B, Tanner SC, Brown AS, Karlin-Neumann G.
    Methods; 2013 Jan 20; 59(1):S20-3. PubMed ID: 23036330
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.
    Koudelakova V, Berkovcova J, Trojanec R, Vrbkova J, Radova L, Ehrmann J, Kolar Z, Melichar B, Hajduch M.
    J Mol Diagn; 2015 Jul 20; 17(4):446-55. PubMed ID: 25956448
    [Abstract] [Full Text] [Related]

  • 10. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
    Laible M, Schlombs K, Kaiser K, Veltrup E, Herlein S, Lakis S, Stöhr R, Eidt S, Hartmann A, Wirtz RM, Sahin U.
    BMC Cancer; 2016 Jul 07; 16():398. PubMed ID: 27389414
    [Abstract] [Full Text] [Related]

  • 11. Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens.
    Yamamoto S, Ibusuki M, Yamamoto Y, Fu P, Fujiwara S, Murakami K, Iwase H.
    Breast Cancer; 2013 Jul 07; 20(3):262-70. PubMed ID: 22362219
    [Abstract] [Full Text] [Related]

  • 12. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M.
    Clin Cancer Res; 2005 Dec 01; 11(23):8348-57. PubMed ID: 16322295
    [Abstract] [Full Text] [Related]

  • 13. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S, Igarashi H, Nagura K, Kamo T, Kawane K, Mori H, Ozawa T, Maeda M, Konno K, Hoshino H, Konno H, Ogura H, Shinmura K, Hattori N, Sugimura H.
    Pathol Int; 2012 Nov 01; 62(11):728-34. PubMed ID: 23121603
    [Abstract] [Full Text] [Related]

  • 14. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
    Nitta H, Kelly BD, Padilla M, Wick N, Brunhoeber P, Bai I, Singh S, Ranger-Moore J, Bieniarz C, Tsuda H, Grogan TM.
    Diagn Pathol; 2012 May 30; 7():60. PubMed ID: 22647525
    [Abstract] [Full Text] [Related]

  • 15. Quantitative PCR--new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.
    Schlemmer BO, Sorensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexo E.
    Scand J Clin Lab Invest; 2004 May 30; 64(5):511-22. PubMed ID: 15276916
    [Abstract] [Full Text] [Related]

  • 16. Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.
    Müller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, Weichert W, Altmann G, Roth C, Winzer KJ, Kristiansen G, Petry C, Dietel M, Denkert C.
    Diagn Mol Pathol; 2011 Mar 30; 20(1):1-10. PubMed ID: 21326033
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection.
    Li Y, Zhang R, Han Y, Lu T, Ding J, Zhang K, Lin G, Xie J, Li J.
    Diagn Pathol; 2016 Sep 10; 11(1):85. PubMed ID: 27613595
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G, Hellenic Cooperative Oncology Group (HeCOG).
    Br J Cancer; 2008 Dec 02; 99(11):1775-85. PubMed ID: 18985033
    [Abstract] [Full Text] [Related]

  • 19. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples.
    Wang X, Wu Y, Song X, Sun C, Wu C, Feng H.
    J Cancer Res Ther; 2017 Dec 02; 13(4):730-734. PubMed ID: 28901323
    [Abstract] [Full Text] [Related]

  • 20. High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence.
    Wasserman BE, Carvajal-Hausdorf DE, Ho K, Wong W, Wu N, Chu VC, Lai EW, Weidler JM, Bates M, Neumeister V, Rimm DL.
    Lab Invest; 2017 Dec 02; 97(12):1521-1526. PubMed ID: 28892092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.